Graph Therapeutics Raises Over $10 Million to Build AI-Driven Precision Medicines for Inflammatory Diseases

2. Accelerate Internal Drug Discovery Pipeline

The fresh capital will push Graph's own precision medicine programs for inflammation and immunology toward lead optimization and preclinical development — a strategic pivot from powering partners' pipelines to building its own drugs .

3. Scale Proprietary Data Generation

In a strategic partnership with Parse Biosciences, Graph is building one of the largest functional immune cell perturbation atlases. The collaboration leverages Parse's GigaLab technology to profile hundreds of millions of cells from patients with immune diseases, making the immune system's dynamic behavior accessible to AI-first drug discovery .

Investor and Grant Breakdown

The $5 million round was led by Daphni through its Blue fund, which is dedicated to backing science-based European startups . Existing investors SquareOne, Merantix Capital, and NAVEC Investment Management also participated, alongside non-dilutive support from the Austrian Research Promotion Agency (FFG) and Austria Wirtschaftsservice (AWS) .

The Team Behind Graph Therapeutics

Graph Therapeutics was founded by Gregory Vladimer and Robert Sehlke, the same scientific team that built Allcyte — a Vienna-based drug-testing platform acquired by Exscientia for $60 million in June 2021 .

Allcyte pioneered the idea that testing drugs directly on a patient's own cells could predict treatment outcomes better than genetic sequencing alone. Graph represents the next chapter in this approach: instead of powering other companies' pipelines, the team is now building its own precision medicines for inflammation and immunology .

Why It Matters

Traditional drug discovery struggles to decode the complex immune dysfunctions that drive autoimmune and inflammatory diseases. With limited precision medicine options in immunology and inflammation (I&I), Graph's ability to map and perturb patient immune cells at scale could unlock more effective therapies that target the root causes of disease .

By combining a decade of innovation in primary patient disease models with AI, Graph Therapeutics aims to close the translational gap that has long plagued immunology drug development .